Accueil   Diary - News   All news Valneva Initiates Phase I Clinical Study to Evaluate Its SingleShot Vaccine Candidate against Chikungunya

Valneva Initiates Phase I Clinical Study to Evaluate Its SingleShot Vaccine Candidate against Chikungunya

 

Lyon (France), March 13, 2018 – Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announced the initiation of a Phase I clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1553, its live-attenuated vaccine candidate against Chikungunya.

 

The Phase I clinical trial is a randomized, observer-blinded, dose-escalation, multi-center study. It will investigate three different dose levels of VLA1553 in approximately 120 healthy adults vaccinated with a single-shot immunization. The trial design includes the investigation of antibody persistence and an additional vaccination using the highest dose of VLA1553 at 6 and 12 months. This re-vaccination will serve as an intrinsic human viral challenge, aiming to demonstrate that subjects are protected from vaccineinduced viremia thereby indicating potential efficacy of VLA1553 early in clinical development.

 

 

 

Read the press release